First-of-its-kind partnership designed to educate and mobilize patients to imagine a healthier tomorrowDAYTONA BEACH, Fla. and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Ladies Professional Golf Association (LPGA) and Ardelyx (Nasdaq: ARDX), a biopharmaceutical company with a vision of creating a healthier tomorrow for patients, today announced a multi-year partnership naming Ardelyx as an official corporate pharmaceutical Marketing Partner of the LPGA Tour. The exclusive partnership unites two o ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Jefferies lowered its price target on Apogee Therapeutics Inc. (NASDAQ:APGE) to $95 from $98 while keeping its Buy rating on the stock. The analyst also reduced its risk-adjusted peak sales forecast for Apogee’s ’279 combination therapy from $1.8 billion to $1.6 billion to reflect potential limitations in high-risk patients. Jefferies’ price target adjustment on Apogee Therapeutics I ...

Group 1 - Kura Oncology, Inc. is focused on developing targeted cancer therapies for genetically defined leukemias and solid tumors, with several drug candidates in clinical development [2] - The company received FDA approval for KOMZIFTI, a once-daily oral targeted therapy for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia [2] - Early trial results for KOMZIFTI combined with venetoclax and azacitidine showed overall response rates of 65% and 41% in relapsed/refractory NPM1-m and KMT2A-r AML, with higher rates in venetoclax-naïve patients [2] Group 2 - Kura Oncology is noted for its milestone payment of $135 million related to the U.S. commercial sale of KOMZIFTI, indicating significant commercial potential [1] - The company is viewed as a speculative investment in the cancer treatment space, with larger competitors like Johnson & Johnson and Merck being ahead in the market [1] - Despite the potential of Kura Oncology, certain AI stocks are suggested to offer greater upside potential and less downside risk [2]

Core Insights - The addition of metachromatic leukodystrophy (MLD) to the U.S. Recommended Uniform Screening Panel (RUSP) is a significant advancement for newborn screening, enabling early diagnosis and treatment of this severe disease [1][3][5] - Newborn screening (NBS) is recognized as one of the most successful public health programs, with approximately 1 in 500 newborns diagnosed with conditions through NBS, potentially saving over 8,000 infants annually [2][3] - Community-led efforts are crucial for the implementation of newborn screening for MLD, with 14 states already having RUSP-aligned legislation [1][2][8] Company Insights - Orchard Therapeutics, a Kyowa Kirin company, is focused on advancing gene therapy treatments, including the recently approved therapy for MLD, which is the first of its kind for eligible children [5][11] - The company emphasizes the importance of collaboration with researchers, physicians, and patient advocates to enhance and modernize newborn screening programs [3][11] - Orchard Therapeutics aims to leverage its expertise in gene therapy to address severe diseases with high unmet medical needs, including MLD [11][12] Industry Insights - MLD is an ultra-rare neurometabolic disease affecting approximately 1 in 100,000 live births, leading to severe neurological damage and high mortality rates [3][10] - The global recognition of the need for newborn screening for MLD is growing, with several countries, including Norway and Sweden, advancing their screening programs [9] - The successful implementation of newborn screening for MLD in the U.S. is expected to influence other countries to adopt similar measures, highlighting the importance of international collaboration in public health initiatives [8][9]

Core Insights - Kyowa Kirin has appointed Abdul Mullick, Ph.D., as the new President and CEO, effective March 2026, while current CEO Masashi Miyamoto will remain as Chairman [1][2][3] Leadership Transition - The company approved a dual CEO/COO model in March 2025, allowing Mullick to gain insights as the first non-Japanese CEO [2] - The transition back to a single leader model aims to create a more agile management structure to respond to global business changes [3] Strategic Focus - As CEO, Mullick will drive the execution of the company's Vision for 2030, focusing on Bone/Mineral, Intractable Haematological Diseases/Haemato-Oncology, and Rare Diseases [3][4] Mullick's Background - Mullick joined Kyowa Kirin in 2017 and has held various leadership roles, including President of the Europe/Middle East/Africa region and COO [4][5] - He has a Ph.D. in Molecular Biology from the University of Bristol and a BSc from Kingston University, both in the UK [5] Company Mission - Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value, focusing on high unmet medical needs [6]

Core Insights - Kura Oncology has completed its first U.S. commercial sale of KOMZIFTI™ (ziftomenib), marking a significant milestone for the company [1] - The sale triggers a $135 million milestone payment from Kyowa Kirin, expected to be received by Kura before year-end [1] - KOMZIFTI was approved by the U.S. FDA on November 13, 2025, for treating adults with relapsed or refractory NPM1-mutated acute myeloid leukemia [1][2] Company Overview - Kura Oncology is focused on precision medicines for cancer treatment, with a pipeline of small molecule drug candidates targeting cancer signaling pathways [2] - The company is commercializing KOMZIFTI™, a once-daily oral menin inhibitor, and is advancing research in menin inhibition and farnesyl transferase inhibition [2]

Kura Oncology Conference Call Summary Company Overview - **Company**: Kura Oncology (NasdaqGS: KURA) - **Product**: Komzifti (ziftomenib) - **Industry**: Oncology, specifically focusing on acute myeloid leukemia (AML) Key Points FDA Approval - The FDA granted full approval for Komzifti, a once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated AML, marking a significant milestone for Kura Oncology [4][30] - The approval was ahead of the PDUFA target action date of November 30, 2025, indicating a strong benefit-risk profile for patients [4][30] Clinical Data - Komzifti demonstrated a 21.4% complete remission (CR) plus complete remission with partial hematologic recovery (CRh) rate in a study of 112 patients [10] - The median duration of response was five months, with a median time to response of 2.7 months [10] - Patients who achieved a response had a median overall survival of 18.4 months compared to 3.5 months for non-responders [10] - Safety data indicated that Komzifti was generally well tolerated, with most adverse reactions being grade one or two [11] Treatment Implications - Komzifti is positioned as a foundational therapy for acute leukemias, with ongoing studies exploring its use in frontline therapy and combinations with other treatments [5][18] - Approximately 20% of patients are refractory to frontline treatment, and 50% of those achieving complete remission will relapse, highlighting the urgent need for effective therapies [8] Commercial Strategy - Kura has prepared for the U.S. launch of Komzifti, with a launch price set at $48,500 for a one-month supply [28] - The U.S. market for NPM1-mutated relapsed refractory AML is estimated to be between $350 million and $400 million annually, with potential for a larger opportunity in frontline AML [29] - Kura's commercial strategy focuses on driving adoption, ensuring broad access, and leveraging partnerships, particularly with Kyowa Kirin [25][26] Market Dynamics - The company anticipates that Komzifti will become the preferred option in the relapsed refractory NPM1-mutated AML setting due to its best-in-class profile and ease of use [21][22] - Kura's field teams are targeting over 4,000 healthcare providers to maximize reach and impact [25] Future Developments - Ongoing trials are evaluating Komzifti in various treatment settings, including combinations with standard chemotherapy regimens [18][19] - The company is committed to generating robust clinical data to support Komzifti's adoption and integration into treatment guidelines [19] Safety and Drug Interactions - Komzifti does not require dosage reduction when administered with strong CYP3A4 inhibitors, enhancing its compatibility with supportive therapies [12][13] - The absence of significant drug-drug interactions is a key advantage over competing therapies [13][24] Conclusion - Kura Oncology is poised to transform AML treatment with Komzifti, supported by a strong clinical profile, strategic commercial plans, and a commitment to patient care [30]

Core Insights - Ardelyx, Inc. is participating in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2025 [1] - The company focuses on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs [3] Company Overview - Ardelyx has two commercial products approved in the United States: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [3] - The company is developing RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas [3] - Ardelyx has international agreements for the commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] - Knight Therapeutics is responsible for commercializing IBSRELA in Canada [3]

Financial Data and Key Metrics Changes - Collaboration revenue from the Kyowa Kirin partnership for Q3 2025 was $20.8 million compared to no revenue in Q3 2024 [16] - Research and development expenses for Q3 2025 were $67.9 million, up from $41.7 million in Q3 2024 [16] - General and administrative expenses for Q3 2025 were $32.8 million, compared to $18.2 million in the same period of 2024 [16] - Net loss for Q3 2025 was $74.1 million, compared to a net loss of $54.4 million in Q3 2024 [16] - Pro forma cash as of September 30, 2025, was $609.7 million, down from $727.4 million as of December 31, 2024 [17] Business Line Data and Key Metrics Changes - The company is advancing its clinical pipeline, particularly with Zifduminib, a menin inhibitor for acute myeloid leukemia (AML) [3][4] - Zifduminib's clinical data from the COMET-001 study showed a favorable benefit-risk profile, with high rates of complete remission and minimal residual disease negativity [5][6] - The company is targeting enrollment at over 150 global sites for its COMET-017 frontline phase 3 trials [7] Market Data and Key Metrics Changes - The company is preparing for the anticipated commercial launch of Zifduminib, with disease awareness campaigns exceeding targets [9] - The commercial organization is fully mobilized and ready to execute upon approval, with a focus on specialty hematologists and large academic institutions [23] Company Strategy and Development Direction - The company aims to position Zifduminib as the menin inhibitor of choice for eligible patients, with a focus on addressing unmet needs beyond the relapsed refractory setting [4] - The dual pipeline strategy includes both menin inhibition and farnesyl transferase inhibitors, which are seen as strategically important for growth [12] - The company plans to submit data for Zifduminib to the NCCN guidelines shortly after FDA approval [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a successful review outcome for Zifduminib, with a PDUFA target action date of November 30, 2025 [3][18] - The company remains in a strong financial position to support its pipeline and commercialization activities, expecting significant milestone payments in the near term [14][17] - Management highlighted the importance of safety and tolerability in differentiating Zifduminib from competitors, especially in the context of the recent black box warning for Torsades [28][30] Other Important Information - The company plans to host a virtual investor and analyst event to discuss ASH presentations on December 8, 2025 [6] - The company has received two $30 million milestone payments for the COMET-017 trials, bringing total milestones received this year to $105 million [14] Q&A Session Summary Question: What account types are being targeted for Zifduminib launch? - The focus is on specialty hematologists, with a mix of large academic institutions and community oncology practices [23][24] Question: What to expect from the ASH update? - The ASH presentations will include more evaluable patients, updated MRD negativity data, and longer follow-up information [25][26] Question: How does the new label impact the NPM1 launch? - The black box warning for Torsades is significant, especially for the NPM1 population, and differentiates Zifduminib based on its favorable safety profile [30][31] Question: What market share is expected relative to competitors? - While specific market share expectations were not provided, the company anticipates capturing a majority share based on Zifduminib's best-in-class profile [39] Question: What are the dynamics with FDA regulatory engagement? - The company has not noticed any changes in cadence with the FDA and remains on track for the November 30 PDUFA date [67]

Core Insights - Kura Oncology has received a $30 million milestone payment from Kyowa Kirin for the dosing of the first patient in the second Phase 3 trial of ziftomenib, bringing total milestone payments received to $105 million, with expectations of up to $315 million in additional near-term milestones [1][2]. Group 1: Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, with a pipeline targeting cancer signaling pathways and addressing hematologic malignancies and solid tumors [3]. - The company is developing ziftomenib, a menin inhibitor aimed at specific genetic drivers of acute myeloid leukemia (AML), and is pioneering advancements in menin inhibition for both acute leukemias and solid tumors [3]. Group 2: Clinical Trials - The KOMET-017 trial consists of two independent, global, randomized double-blind, placebo-controlled Phase 3 trials evaluating ziftomenib in combination with intensive and non-intensive chemotherapy regimens for patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML [2]. - Kura believes that KOMET-017 is the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings [2].